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Abstract
Background: Neurocysticercosis (NCC) is an invasive parasitic infection of the
central nervous system caused by the larval stage of the tapeworm Taenia solium.
The clinical manifestations of NCC depend on the parasitic load and location of
infection, as well as the developmental stage of the cysticerci and host immune
response, with symptoms ranging from subclinical headaches to seizures,
cerebrovascular events, and life‑threatening hydrocephalus. Racemose NCC
represents a particularly severe variant of extraparenchymal NCC characterized
by the presence of multiple confluent cysts within the subarachnoid space and is
associated with increased morbidity and mortality, as well as a decreased response
to treatment. Albendazole is the preferred drug for the treatment of racemose NCC
due to its superior cerebrospinal fluid penetration compared to praziquantel and
the ability to be used concomitantly with steroids.
Case Description: In this report, we describe a 39‑year‑old man recently
emigrated from Mexico with racemose NCC and hydrocephalus successfully
treated with prolonged albendazole treatment, high‑dose dexamethasone, and
ventriculoperitoneal shunt placement for the relief of obstructive hydrocephalus.
Conclusions: Treatment of racemose NCC represents a significant clinical
challenge requiring multimodal intervention to minimize infectious‑ and
treatment‑related morbidity. We review the clinical, diagnostic, and therapeutic
features relevant to the management of this aggressive form of NCC.
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INTRODUCTION
Neurocysticercosis (NCC) is a common parasitic
infection of the central nervous system (CNS) caused
by the tapeworm Taenia solium. Infection is typically
characterized by the presence of intraparenchymal
cysts within the cerebral hemispheres at the gray‑white
junction and NCC is the most frequent cause of
acquired epilepsy in the developing countries.[17] Parasitic
infestation is endemic to South and Central America,
Southeast Asia, China, and Sub‑Saharan Africa[6] and
is of increasing importance in the United States due
to high volumes of immigration from these endemic

areas.[6,14,24] Extraparenchymal NCC is less common
than the intraparenchymal form and is defined as
NCC involving the subarachnoid, meningeal, and
intraventricular space. Extraparenchymal NCC presents
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unique diagnostic and therapeutic challenges compared
to the intraparenchymal form. The racemose variant of
extraparenchymal NCC represents a particularly aggressive
infection and is associated with relatively increased
morbidity and mortality and decreased responsiveness to
medical treatment. The variant is characterized by the
presence of multilobulated confluent cysts within the
basal subarachnoid space that appear “grape‑like” both
radiographically and pathologically.[6] In this report, we
describe the successful management of a patient with
extensive racemose NCC and hydrocephalus treated
with cerebrospinal fluid (CSF) diversion and prolonged
administration of albendazole and corticosteroids with
complete radiographic and clinical resolution of infection.
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CASE REPORT
A 39‑year‑old male presented to the emergency
room with a complaint of worsening headaches and
visual decline. The patient emigrated from Mexico
13 months prior to presentation and reported no
other significant medical history. He described diffuse
headaches that had progressed over a 1‑month period
with new‑onset bilateral visual impairment and nausea
for the last week. His neurologic exam was nonfocal,
however, the ophthalmologic evaluation revealed
bilateral papilledema and diminished visual acuity. He
was afebrile on presentation and without meningeal
irritation signs. Initial laboratory findings indicated a
normal white blood cell count of 7400/mm3 with 73%
polymorphonuclear leukocytes, 21% lymphocytes, and
1% eosinophils. A head computed tomography (CT)
scan demonstrated hydrocephalus with transependymal
flow and a multilobulated hypodense mass in the basal
cisterns. Subsequent magnetic resonance imaging (MRI)
was performed which demonstrated the presence of too
numerous to count nonenhancing, T2‑hyperintense
cystic lesions in the lateral ventricles and subarachnoid
spaces including the bilateral sylvian fissures and
cerebellopontine angles, as well as the suprasellar,
interpeduncular, and prepontine cisterns with the largest
cyst measuring 21 mm in diameter and exerting mild
mass effect upon the brainstem [Figure 1]. Minor sylvian
fissure enhancement was noted bilaterally, however,
magnetic resonance angiography (MRA) showed no large
vessel stenosis or occlusion. A screening MRI of the spine
demonstrated a small subarachnoid cystic lesion at the
level of the conus and multiple septations at the S1–S2
level. A lumbar puncture was performed, and an elevated
opening pressure was documented. CSF analysis revealed
a mild lymphocytic pleocytosis with 60 white blood
cells/mm3 (96% lymphocytes, 4% eosinophils). The initial
CSF protein level was 106 mg/dL with a glucose level
of 54 mg/dL. CSF cysticercus antibody ELISA testing
was positive, and a diagnosis of racemose NCC was

Figure 1: (a) Axial T2-weighted magnetic resonance imaging
demonstrating multiple confluent cystic lesions in the basal
cisterns and sylvian fissures. (b) Fluid-attenuated inversion recovery
magnetic resonance imaging showing multiple cystic lesions with the
largest cyst measuring 21 mm in maximal diameter (dashed arrow)
and mild mass effect on the brainstem. (c) Sagittal T1-weighted
magnetic resonance imaging postgadolinium administration
showing hydrocephalus and cystic lesions in suprasellar, prepontine,
and foramen magnum cisterns. (d) Fluid-attenuated inversion
recovery magnetic resonance imaging demonstrating multiple
cystic lesions within the lateral ventricles bilaterally (arrows) with
enlarged ventricles and transependymal flow

made based on the immunoassay results, neuroimaging
findings, and a history of recent emigration from Mexico.
After extensive discussion between the neurosurgical and
infectious diseases teams, we elected to proceed with
placement of a ventriculoperitoneal shunt to ameliorate
his elevated intracranial pressure and communicating
hydrocephalus. High‑dose dexamethasone (4 mg QID)
was initiated followed by administration of prolonged
albendazole (10 mg/kg/day) treatment. The patient
experienced immediate relief of his visual deficit
following the CSF diversion treatment. He maintained
a mild headache disorder that responded well to
steroids, and he was able to be slowly weaned off of this
medication over a 12 month period. MRI scan performed
at that time revealed complete radiographic resolution
of his subarachnoid, spinal, and intraventricular cystic
lesions with very mild persistent meningeal enhancement
[Figure 2]. A serum cysticercus antigen ELISA test was
nonreactive, and albendazole was discontinued.

DISCUSSION
Cysticercosis is the most common helminthic infection
of the CNS with infection occurring primarily through
the ingestion of eggs of the parasitic tapeworm
T. solium.[13] The eggs hatch within the digestive system
and the released oncospheres penetrate the intestinal
mucosa to enter the circulation. The oncospheres are then
passively transported to various tissues including the brain,
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Figure 2: (a) Axial T2-weighted magnetic resonance imaging
showing cyst resolution within the basal cisterns and sylvian
fissures. (b) Fluid-attenuated inversion recovery magnetic resonance
imaging showing resolution of the multiple cystic lesions within the
lateral ventricles and hydrocephalus

muscle, and eyes where the parasites form larval cysts, or
cysticerci. Extraparenchymal NCC occurs as the cysticerci
reach the ventricles through the choroid plexus where they
may pass freely or become attached to the ependyma.[16]
Intraventricular infection appears to be more frequent than
previously believed with recent series documenting the
presence of parasitic cysts in up to 30% of patients with
NCC.[9] Displacement of the cysts from the ventricles via
the CSF may lead to infection within the basal cisterns,
sylvian fissures, and cortical and spinal subarachnoid
spaces. Excessive basal subarachnoid infection involving
numerous parasitic membranes and enlarged vesicular
cysts accompanied by a relative lack of scolices is termed
racemose NCC, although no definitive diagnostic criteria
for this rare but severe variant have been described.[6]
The diagnosis of racemose NCC is typically based on
neuroimaging, serum and CSF laboratory evaluation,
and clinical, epidemiologic data including immigration
from or frequent travel to disease‑endemic areas.
Contrast‑enhanced MRI is the imaging modality of
choice for the detection of extraparenchymal NCC
as CT has limited sensitivity for identification of
intraventricular and small subarachnoid cysts.[16] Lesions
typically appear as hyperintense on T2‑weighted
sequences and provide a clear delineation of the cyst
wall and the presence of obstructive or communicating
hydrocephalus. Contrast evaluation is important to
determine the extent of the host inflammatory response
including ependymitis and basal arachnoiditis, as well as
the evolutionary stage of the parasite. While the clinical
and neuroimaging findings are of paramount importance,
serologic testing may provide additional data, especially
in patients without an appropriate epidemiologic history.
Peripheral eosinophilia is a common but nonspecific
finding with NCC.[8] Similarly, the presence of CSF
eosinophils is frequently indicative of NCC and is a
helpful in differentiating NCC from other forms of
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infectious chronic meningitis, although this finding has
been reported to occur in only 15% of patients.[9] The
most common CSF abnormalities observed with NCC
are a mild‑moderate lymphocytic pleocytosis and increase
in protein with the levels varying according to parasitic
burden and location of the infection. Positive serum
and CSF immunoassays for detection of anticysticercal
antibodies are highly suggestive of NCC infection in
the appropriate clinical setting, although false‑negative
results are a well‑recognized limitation.[8] The sensitivity
of these immunoassays has not been established for the
racemose variant but would be expected to be increased
given the robust inflammatory reaction typically elicited
with subarachnoid infection.
The intraventricular and cisternal forms of NCC typically
manifest in a more clinically aggressive manner than
parenchymal infection and frequently cause intracranial
hypertension due to CSF outflow obstruction or
inflammatory basal arachnoiditis.[21] Cysts within the
ventricular cavities may be free floating and cause
obstruction at the foramina of Monro, sylvian aqueduct,
or fourth ventricle and may present with rapid clinical
deterioration secondary to acute hydrocephalus. These
cysts may also become attached to the ependymal wall
of the ventricle and result in ependymitis following cyst
degeneration that may lead to intraventricular loculation
and make CSF diversion more problematic. Similarly, cyst
degeneration within the subarachnoid space may elicit
an accompanying host inflammatory response with basal
arachnoiditis, vasculitis, elevated intracranial pressure,
and subacute to chronic hydrocephalus requiring CSF
diversion. In 2002, DeGiorgio et al. demonstrated that
patients with heavy cyst burdens and hydrocephalus
carried the highest risk of mortality with NCC,
primarily because of elevated intracranial pressure and
shunt‑related problems.[7] Similarly, Colli et al. reported
a 30.8% mortality in patients who required placement
of a ventriculoperitoneal shunt and a >80% rate of
shunt failure secondary to shunt obstruction due to
proteinaceous debris.[4] In addition to hydrocephalus,
the active inflammatory process may lead to vasculitis
and cerebrovascular complications. Angiography or MRA
may reveal segmental narrowing or occlusion of large
vessels within the basal cisterns and sylvian fissures, with
the majority of infarcts occurring in the lenticulostriate
artery distributions.[3] Basal meningitis may also cause
cranial nerve dysfunction due to fibrous entrapment.[16]
Callacondo et al. recently described that extension of
infection to the spinal subarachnoid space is very common
in racemose NCC, with spinal involvement documented
in 17 of 28 patients in their prospective study leading the
authors to recommend that screening MRI of the spine
be performed in basal subarachnoid disease to document
spinal involvement, prevent complications, and monitor
for recurrent infection.[2]
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No consensus exists regarding the optimal treatment of
racemose NCC including the duration of anthelmintic
treatment and the role of surgical intervention. In
patients presenting with hydrocephalus, the priority
is relief of raised intracranial pressure.[14] Obstructive
hydrocephalus due to intraventricular cysts is best
managed endoscopically via cyst removal or drainage
and often obviates the need for permanent shunt
placement.[8,19] Intraventricular cysts may be freely mobile
and imaging immediately prior to neuroendoscopic
intervention is recommended to confirm the location
of the cyst. A relative contraindication for endoscopic
removal of intraventricular cysts is the presence of
significant ependymal enhancement as this typically
indicates dense adhesion between the parasitic cyst
and the ependymal wall with attempted cyst removal
associated with neurologic injury and intraventricular
hemorrhage.[10,20] A role for endoscopic or microsurgical
removal of subarachnoid cysts within the basal cisterns
and sylvian fissures is less established due to frequently
high cyst burden and widespread subarachnoid
distribution and inflammatory response. Giant
(>5 cm) subarachnoid cysts with associated mass effect
and intracranial hypertension are most often managed
surgically, although Proaño et al. demonstrated complete
resolution of giant cysts in 19 of 33 patients treated
medically with prolonged multicourse anthelmintic and
corticosteroid therapy.[18] Couldwell et al. suggested that
surgical therapy be reserved for cisternal forms of NCC if
initial medical management fails or experiences neurologic
decline as conventional microsurgical approaches have
been associated with significant morbidity, likely due
to the presence of arachnoiditis with adherence of the
cyst walls to cranial nerves and arteries.[5] More recently,
several authors have described minimally invasive
keyhole or endoscopic approaches to the basal cisterns
to achieve cyst drainage, although the utility of these
approaches for extensive subarachnoid disease has yet
to be established.[1] Fortunately, spillage of cyst contents
with these approaches has not proven to exacerbate
the inflammatory response in the postoperative period,
although careful attention to this concern and copious
intraoperative irrigation are recommended.[11,12]
In our patient with hydrocephalus and relatively rapid
progression of visual loss, given the bilateral sylvian
fissure involvement and absence of any dominant cystic
lesion or focal neurologic deficits, we elected to proceed
with placement of a ventriculoperitoneal shunt prior to
initiating therapy directed against the invasive infection.
Delayed exacerbation of intracranial hypertension
frequently occurs several days following administration
of cysticidal agents as a result of cyst degeneration and
subsequent host inflammatory response with the release
of proinflammatory cytokines.[6,23] For this reason, steroids
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should be administered concurrently with anthelmintic
therapy to reduce the inflammatory response.
Subarachnoid cysts are considered less responsive to
pharmacologic therapy compared to intraparenchymal
lesions, with albendazole the preferred drug for
treatment of racemose NCC due to its superior CSF
penetration compared to praziquantel.[8] Additionally,
the CNS distribution of albendazole is less affected
by steroid administration.[22] The dose and duration of
treatment must be individually tailored to each patient
depending on their parasitic burden and clinical and
radiographic response to treatment with the treatment
course frequently longer than that prescribed for the
parenchymal disease. Aggressive medical treatment
has been shown to decrease the incidence of shunt
malfunction, which has been directly linked to poorer
clinical outcome.[15] For patients with giant cysts,
Proaño et al. achieved excellent results with a 4 weeks
course of albendazole, although more than half of their
patients required more than one treatment course to
achieve cyst resolution. 4 of the 33 patients in their study
required 3 or more months of therapy and 10 patients
also received praziquantel following a failure of the cysts
to respond to albendazole.[18]

CONCLUSION
In our patient, we reported the successful clinical
resolution of racemose NCC following CSF diversion
and prolonged anthelmintic therapy and corticosteroid
administration to prevent the development of chronic
subarachnoid inflammation. No shunt complications or
revisions occurred, and a complete radiographic response
was observed. Racemose NCC represents a, fortunately,
rare but aggressive form of extraparenchymal NCC
often resulting in basilar arachnoiditis, vasculitis, and
cranial neuropathy. Proper recognition of this infection
and appropriate management with careful consideration
of the deleterious effects of the attendant host
inflammatory response to cyst degeneration is necessary
to reduce patient morbidity and mortality. Racemose
NCC accompanied by intracranial hypertension and
hydrocephalus is associated with poorer clinical outcomes,
often related to ventriculoperitoneal shunt infection
and malfunction. Vigilant clinical and radiographic
monitoring of response to treatment is imperative to
reduce neurologic sequelae and infection relapse as
prolonged, or multicourse medical therapy is frequently
necessary.
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